Parkinsonism & related disorders最新文献

{"title":"Mortality in elderly Parkinson's disease patients with long-term care needs: A nationwide population-based study in Korea","authors":"Seung Hyun Lee ,&nbsp;Mina Kim ,&nbsp;Woon Chang Heo ,&nbsp;Joong-Goo Kim ,&nbsp;Jung Seok Lee ,&nbsp;Ji Hoon Kang ,&nbsp;Jooyoung Lee","doi":"10.1016/j.parkreldis.2024.107150","DOIUrl":"10.1016/j.parkreldis.2024.107150","url":null,"abstract":"<div><h3>Background</h3><p>The effects of long-term care insurance (LTCI) in reducing medical costs and utilization among older adults have been reported. This study aims to investigate the mortality in patients with Parkinson's disease (PD) requiring LTCI and its relationships with economic status.</p></div><div><h3>Methods</h3><p>This study was conducted using the database of the Korean National Health Insurance Service (NHIS)-Senior Cohort between 2008 and 2019. A total of 5937 patients with PD were included. Hazard ratios (HRs) of mortality associated with LTCI were estimated using a Cox regression model. Potential confounders such as demographics and comorbidities were adjusted.</p></div><div><h3>Results</h3><p>Out of 5937 PD patients, 821 required LTCI, and 5116 did not. Compared to PD patients without LTCI, PD patients with LTCI were older and exhibited a higher comorbidity burden. The overall incidence rate of mortality was 18.63 per 100 person-years in PD patients with LTCI. PD patients requiring LTCI were associated with an increased HR of 3.61 (95 % CI = 3.13–4.16) for mortality compared to PD patients not eligible for LTCI. Low-income status with LTCI was associated with the highest mortality risk (HR = 4.54, 95 % CI = 3.38–6.09), compared to middle-income status (HR = 3.47, 95 % CI = 2.64–4.61) and high-income status (HR = 3.53, 95 % CI = 2.91–4.91).</p></div><div><h3>Conclusions</h3><p>Our study suggests that older PD patients requiring LTCI with low economic status have a higher risk of death. Continuous policy efforts to reduce the mortality risk in this group are needed.</p></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107150"},"PeriodicalIF":3.1,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142229702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clonal hematopoiesis with DNMT3A mutations is associated with multiple system atrophy","authors":"Seungmin Lee ,&nbsp;Han-Joon Kim ,&nbsp;Seoyeon Kim ,&nbsp;Bora Jin ,&nbsp;HoYoung Jeon ,&nbsp;Kyung Ah Woo ,&nbsp;Jung Hwan Shin ,&nbsp;Chansub Lee ,&nbsp;Choonghyun Sun ,&nbsp;Hogune Im ,&nbsp;Hongyul An ,&nbsp;Young Il Koh ,&nbsp;Su-Yeon Choi ,&nbsp;Beomseok Jeon","doi":"10.1016/j.parkreldis.2024.107145","DOIUrl":"10.1016/j.parkreldis.2024.107145","url":null,"abstract":"<div><h3>Background</h3><p>Clonal hematopoiesis of indeterminate potential (CHIP) is associated with cardiovascular diseases and other disorders, possibly via inflammation. Recent research suggests a connection of CHIP with neurodegenerative disorders.</p></div><div><h3>Objective</h3><p>We aimed to investigate the association between multiple system atrophy (MSA) and CHIP.</p></div><div><h3>Methods</h3><p>We included 100 patients with MSA and 4457 controls. Targeted sequencing of peripheral blood DNA samples was performed, focusing on a panel of 25 genes commonly.</p></div><div><h3>Linked to chip</h3><p>The prevalence of CHIP in patients with MSA was assessed against controls at variant allele frequency (VAF) thresholds of 1.5 % and 2.0 %.</p></div><div><h3>Results</h3><p>DNMT3A mutation rates were significantly higher in patients with MSA, with a VAF of 1.5 %, which remained significant after adjusting for age and sex (adjusted odds ratio, 1.848; 95 % CI, 1.024–3.335; p = 0.0416).</p></div><div><h3>Conclusion</h3><p>Our results suggest an association between DNMT3A mutations and MSA.</p></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107145"},"PeriodicalIF":3.1,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142232470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral thalamic glioblastoma presenting as parkinsonism: A case report","authors":"Daniel Mareček,&nbsp;Viktorie Kopecká,&nbsp;Radoslav Matěj,&nbsp;Ondřej Strýček","doi":"10.1016/j.parkreldis.2024.107147","DOIUrl":"10.1016/j.parkreldis.2024.107147","url":null,"abstract":"","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107147"},"PeriodicalIF":3.1,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142229785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A useful cognitive motor dual task paradigm in prodromal and manifest Huntington’s disease","authors":"Emma Churchill ,&nbsp;Shelby Hughes ,&nbsp;Andrew Hall ,&nbsp;Braden Culbert ,&nbsp;Daniel J. Goble ,&nbsp;Jody Corey-Bloom ,&nbsp;Paul E. Gilbert","doi":"10.1016/j.parkreldis.2024.107119","DOIUrl":"10.1016/j.parkreldis.2024.107119","url":null,"abstract":"<div><h3>Introduction</h3><div>Individuals with Huntington's disease (HD) experience increased difficulty with balance throughout disease progression. Adding a simultaneous cognitive task to a balance assessment, referred to as a dual task (DT) paradigm, may have a deleterious effect on balance, which can be expressed in terms of a Dual Task Cost (DTC), relative to a single task (ST) condition. The aim of this study is to explore whether a cognitive-motor DT paradigm uncovers balance deficits in prodromal (Pro-HD) and manifest HD, compared to healthy adults (HA).</div></div><div><h3>Methods</h3><div>Balance under ST and DT conditions was examined using the BTracks Balance Plate and Balance software in 30 individuals with HD, 17 individuals with Pro-HD, and 20 HA. During the DT condition, participants were simultaneously administered a version of the Paced Auditory Serial Addition Test (PASAT). DTC is calculated as the relative ratio of ST to DT, controlling for ST performance: DTC= (ST − DT)/ST x100.</div></div><div><h3>Results</h3><div>The HA group performed significantly better than the HD group on both the ST and DT conditions (<em>p</em> &lt; 0.01), while balance scores between the HA and the Pro-HD groups were not significantly different. The DTC scores, however, were significantly better in the HA compared to both the HD (p &lt; 0.001) and Pro-HD (p &lt; 0.05) groups.</div></div><div><h3>Conclusion</h3><div>Our findings indicate that the addition of a cognitive task interferes with participant's balance, reflecting real-life performance, and may have additional value for estimating transition to manifest disease, appraising fall risk, or serving as a valid outcome measure in observational and interventional trials in HD.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107119"},"PeriodicalIF":3.1,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1353802024011313/pdfft?md5=610191a71fe05142942c7245a35df3ab&pid=1-s2.0-S1353802024011313-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative susceptibility mapping analyses of white matter in Parkinson's disease using susceptibility separation technique","authors":"Masahiro Nakashima ,&nbsp;Hirohito Kan ,&nbsp;Tatsuya Kawai ,&nbsp;Kazuhisa Matsumoto ,&nbsp;Takatsune Kawaguchi ,&nbsp;Yuto Uchida ,&nbsp;Noriyuki Matsukawa ,&nbsp;Akio Hiwatashi","doi":"10.1016/j.parkreldis.2024.107135","DOIUrl":"10.1016/j.parkreldis.2024.107135","url":null,"abstract":"<div><h3>Introduction</h3><p>To apply susceptibility separation on quantitative susceptibility mapping (QSM) images of Parkinson's disease (PD) patients to obtain more accurate images and gain pathophysiological insights.</p></div><div><h3>Methods</h3><p>This retrospective study included subjects who underwent head MRI, including QSM between March 2016 and March 2018. Patients with PD were categorized as having mild cognitive impairment (PD-MCI), or normal cognition (PD-CN); healthy controls (HC) were also enrolled. Susceptibility separation generated positive (QSM+) and negative susceptibility (QSM-) labels. Voxel-based whole-brain susceptibility and atlas-based susceptibility were compared among groups on white matter. Correlations between susceptibility and Montreal Cognitive Assessment (MoCA) scores were analyzed.</p></div><div><h3>Results</h3><p>Overall, 65 subjects (mean age 72 years ±6, 35 men) were included. White-matter regions with significant (<em>P</em> &lt; 0.05) group differences were found for QSM+ (HC &gt; PD-MCI, PD-CN &gt; PD-MCI) and QSM- (PD-MCI &gt; HC, PD-MCI &gt; PD-CN). In the atlas-based analyses, PD-MCI exhibited lower QSM + values (vs. HC; <em>P</em> = 0.002, vs. PD-CN; <em>P</em> = 0.001), and higher QSM-values (vs. HC; <em>P</em> = 0.02, vs. PD-CN; <em>P</em> = 0.03) in the genu of corpus callosum (gCC). QSM+ and QSM-showed significant positive and negative correlations with MoCA (<em>P</em> &lt; 0.05). In the gCC, partial correlation analyses revealed a positive correlation between QSM+ and MoCA (R = 0.458, <em>P</em> &lt; 0.001) and a negative correlation between QSM- and MoCA (R = −0.316, <em>P</em> = 0.01).</p></div><div><h3>Conclusion</h3><p>QSM utilizing susceptibility separation is valuable for assessing white matter in PD patients, where nerve fiber loss potentially influences cognitive function.</p></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107135"},"PeriodicalIF":3.1,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142229703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validating new symptom emergence as a patient-centric outcome measure for PD clinical trials","authors":"Haotian Zou ,&nbsp;Glenn T. Stebbins ,&nbsp;Tanya Simuni ,&nbsp;Sheng Luo ,&nbsp;Jesse M. Cedarbaum","doi":"10.1016/j.parkreldis.2024.107118","DOIUrl":"10.1016/j.parkreldis.2024.107118","url":null,"abstract":"<div><h3>Introduction</h3><div>Tracking of emergent symptoms (ES) in de novo Parkinson Disease (PD) patients using Parts Ib and II of the MDS-UPDRS rating scale has been proposed as an outcome measure for PD clinical trials, based on observations in the Safety, Tolerability and Efficacy Assessment of Isradipine for PD (STEADY-PD3) clinical trial.</div></div><div><h3>Methods</h3><div>Individual item-level data was extracted from the SURE-PD3 study (coded as “PD-1018” in the C-path pooled dataset). We sought to confirm the observations made in the STEADY-PD3 dataset by analyzing data from a different Phase 3 clinical trial, the Phase 3 Study of Urate Elevation in Parkinson Disease (SURE-PD3), in which MDS-UPDRS was assessed more frequently than the 12-month intervals in STEADY-PD3, using similar methodology.</div></div><div><h3>Results</h3><div>We were able to broadly validate results that demonstrated the frequency of ES, lack of impact of the introduction of symptomatic medications, and in the reduction in sample size required to demonstrate slowing of disease progression at a group level compared with the traditional total MDS-UPDRS summed score scoring methods. Counts of ES generally correlated modestly with summed MDS-UPRDS scores, both for the various sub-parts and for the overall scale as well. However, instability of individual item responses, especially during the first 6 months of observation complicated the assessment of the temporal evolution and stability of ES over time in the course of the SURE-PD3 study.</div></div><div><h3>Conclusion</h3><div>Further validation using data sets with frequent administration of MDS-UPDRS is necessary to assess value of this approach as an outcome measure in PD clinical trials.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107118"},"PeriodicalIF":3.1,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142359649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Involvement of the basal forebrain and hippocampus in memory deficits in Parkinson's disease","authors":"Haruhi Sakamaki-Tsukita ,&nbsp;Atsushi Shima ,&nbsp;Daisuke Kambe ,&nbsp;Koji Furukawa ,&nbsp;Akira Nishida ,&nbsp;Ikko Wada ,&nbsp;Kenji Yoshimura ,&nbsp;Yusuke Sakato ,&nbsp;Yuta Terada ,&nbsp;Hodaka Yamakado ,&nbsp;Yosuke Taruno ,&nbsp;Etsuro Nakanishi ,&nbsp;Masanori Sawamura ,&nbsp;Yasutaka Fushimi ,&nbsp;Tomohisa Okada ,&nbsp;Yuji Nakamoto ,&nbsp;Laszlo Zaborszky ,&nbsp;Ryosuke Takahashi ,&nbsp;Nobukatsu Sawamoto","doi":"10.1016/j.parkreldis.2024.107134","DOIUrl":"10.1016/j.parkreldis.2024.107134","url":null,"abstract":"<div><h3>Introduction</h3><p>Magnetic resonance imaging (MRI)-determined atrophy of the nucleus basalis of Meynert (Ch4) predicts cognitive decline in Parkinson's disease (PD). However, interactions with other brain regions causing the decline remain unclear. This study aimed to describe how MRI-determined Ch4 atrophy leads to cognitive decline in patients with PD.</p></div><div><h3>Methods</h3><p>We evaluated 137 patients with PD and 39 healthy controls using neuropsychological examinations, MRI, and ¹²³I-ioflupane single-photon emission computed tomography. First, we explored brain areas with regional gray matter loss correlated with Ch4 volume reduction using voxel-based morphometry (VBM). We then assessed the correlation between Ch4 volume reduction and cognitive impairments in PD using partial correlation coefficients (r_par). Finally, we examined whether the regional gray matter loss mediated the association between Ch4 volume reduction and cognitive impairments using mediation analysis.</p></div><div><h3>Results</h3><p>Our PD cohort was “advanced-stage enriched.” VBM analyses revealed that Ch4 volume loss was correlated with volume reduction in the medial temporal lobe in PD (P &lt; 0.05, family-wise error corrected, &gt;29 voxels). Ch4 volume reduction was significantly correlated with verbal memory deficits in PD when adjusted for age, sex, total brain volume, and ¹²³I-ioflupane uptake in the caudate (r_par = 0.28, P &lt; 0.001). The mediation analysis revealed that the hippocampus mediated the effects of Ch4 volumes on verbal memory (average causal mediation effect = 0.013, 95 % CI = 0.006–0.020, P &lt; 0.001).</p></div><div><h3>Conclusion</h3><p>Particularly in advanced-stage PD, Ch4 atrophy was associated with medial temporal lobe atrophy, which played an intermediary role in the relationship between Ch4 atrophy and verbal memory impairments.</p></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107134"},"PeriodicalIF":3.1,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1353802024011465/pdfft?md5=b79168105d43a3434ed339edbd21cd44&pid=1-s2.0-S1353802024011465-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142238441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prominent loss of striatal dopamine transporter binding in frontotemporal lobar degeneration with the MAPT N279K mutation present as early as at prodromal stage without parkinsonism","authors":"Toji Miyagawa,&nbsp;Cynthia Vernon,&nbsp;Scott A. Przybelski,&nbsp;Paul H. Min,&nbsp;Julie A. Fields,&nbsp;Bradford C. Dickerson,&nbsp;Dennis W. Dickson,&nbsp;Kejal Kantarci,&nbsp;Val J. Lowe,&nbsp;Zbigniew K. Wszolek,&nbsp;Bradley F. Boeve","doi":"10.1016/j.parkreldis.2024.107144","DOIUrl":"10.1016/j.parkreldis.2024.107144","url":null,"abstract":"<div><p>Our research found out, from ¹²³I-FP-CIT SPECT scans of three familial frontotemporal dementia (fFTD) individuals with <em>MAPT</em> N279K mutation and similar autopsy findings of frontotemporal degeneration with severe neuronal loss in the substantia nigra, that prominent decrease of dopamine transporter binding (z-score &lt; −5.0) was present at prodromal fFTD without parkinsonism.</p></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107144"},"PeriodicalIF":3.1,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142229704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study","authors":"Violetta Rozani ,&nbsp;Miri Glikshtein Bezimianski ,&nbsp;Joseph Azuri ,&nbsp;Michal Bitan ,&nbsp;Chava Peretz","doi":"10.1016/j.parkreldis.2024.107132","DOIUrl":"10.1016/j.parkreldis.2024.107132","url":null,"abstract":"<div><h3>Background</h3><p>Emerging evidence suggests a potential association between certain anti-diabetic drugs and a reduced risk of Parkinson's disease (PD). Limited population-based studies have investigated users of newer anti-diabetic drugs such as GLP-1 agonists or SGLT2 inhibitors.</p></div><div><h3>Objective</h3><p>The aim of this study was to assess the risk of PD among individuals with type 2 diabetes mellitus (T2DM) who were treated with various types of anti-diabetic drugs over time.</p></div><div><h3>Methods</h3><p>A population-based cohort comprising T2DM patients aged over 30 who used metformin, GLP-1 agonists, thiazolidinediones, sulfonylureas, DPP4 inhibitors, SGLT2 inhibitors, or meglitinides between January 1, 1999 and December 31, 2018. Data were obtained between the diabetes registration and drug purchase databases of Maccabi Healthcare Services. Time-dependent Cox regression models, adjusted for sex, age, and comorbidities were employed to calculate the adjusted hazard ratios (HRs) for the PD risk associated with different anti-diabetic drugs over time.</p></div><div><h3>Results</h3><p>The study population comprised 86,229 T2DM patients, with 53.9 % males. The mean age at the first anti-diabetic drug purchase was 59.0 ± 11.0 and 62.0 ± 11.0 years for men and women respectively. Compared to metformin, several drug types were associated with a significantly lower PD risk: thiazolidinediones (HR = 0.91, 95 % CI:0.074–1.14); DPP4 inhibitors (HR = 0.60, 95 % CI:0.53–0.67); meglitinides (HR = 0.63, 95 % CI:0.53–0.74); GLP-1 agonists (HR = 0.54, 95 % CI:0.39–0.73); and SGLT2 inhibitors (HR = 0.15, 95 % CI:0.10–0.21).</p></div><div><h3>Conclusions</h3><p>Our results suggest a reduced risk of PD with certain anti-diabetic drugs, particularly SGLT2 inhibitors and GLP-1 agonists. Validation through extensive big-data studies is essential to confirm these results and to optimize PD prevention and management.</p></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107132"},"PeriodicalIF":3.1,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1353802024011441/pdfft?md5=0e94c36bf60886f86ebaf635cec0e22c&pid=1-s2.0-S1353802024011441-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142163499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quick MSA-QoL: A validated, abbreviated health-related quality of life questionnaire for use in Multiple System Atrophy","authors":"D. Jugnarain,&nbsp;A. Schrag","doi":"10.1016/j.parkreldis.2024.107143","DOIUrl":"10.1016/j.parkreldis.2024.107143","url":null,"abstract":"<div><h3>Background</h3><p>Health-related quality of life is an important patient-reported outcome, which can be assessed using instruments such as the Multiple System Atrophy (MSA) Quality of Life (MSA-QoL) scale. However, at 40-items its length can prove burdensome, particularly to patients with a disease such as MSA. This can contribute to respondent burden and poor-quality response data.</p></div><div><h3>Objective</h3><p>The objective of this study was to develop an abbreviated MSA-QoL scale for use in clinical practise and trials (Quick MSA-QoL).</p></div><div><h3>Methods</h3><p>A single-factor 15-item scale was developed with data from 310 patients with MSA, using exploratory factor analysis (EFA). A separate dataset (n = 279) was used for analysis of psychometric properties and for confirmatory factor analysis.</p></div><div><h3>Results</h3><p>Missing data was minimal, with even distribution of scores and negligible floor/ceiling effects (0/0.4%). Reliability was high (Cronbach alpha 0.870, test-retest reliability 0.950). Good item-total scale correlations were observed (r = 0.402–0.618), and the overall scale correlated well with other validated questionnaires including the original MSA-QoL (r = 0.862). Confirmatory factor analysis demonstrated acceptable model fit indices. Responsiveness data from re-administration of the Quick MSA-QoL 10 months from baseline testing found the overall scale to be sensitive to change.</p></div><div><h3>Conclusions</h3><p>These data suggest that the Quick MSA-QoL is a suitable and efficient scale for use in clinical trials, minimising respondent burden and maintaining data quality.</p></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"128 ","pages":"Article 107143"},"PeriodicalIF":3.1,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1353802024011556/pdfft?md5=7c15fc51c84f9e5fae14d6069dce3388&pid=1-s2.0-S1353802024011556-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142163498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}